Premium
First‐in‐human trial of nanoelectroablation therapy for basal cell carcinoma: proof of method
Author(s) -
Nuccitelli Richard,
Wood Ryan,
Kreis Mark,
Athos Brian,
Huynh Joanne,
Lui Kaying,
Nuccitelli Pamela,
Epstein Ervin H.
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12303
Subject(s) - seborrheic keratosis , basal cell carcinoma , scars , basal cell , actinic keratosis , medicine , carcinoma , human skin , pathology , ablation , biology , genetics
This nanoelectroablation therapy effectively treats subdermal murine allograft tumors, autochthonous basal cell carcinoma (BCC) tumors in Ptch1+/‐K14‐Cre‐ER p53 fl/fl mice, and UV‐induced melanomas in C57/BL6 HGF/SF mice. Here, we described the first human trial of this modality. We treated 10 BCCs on three subjects with 100–1000 electric pulses 100 ns in duration, 30 kV/cm in amplitude, applied at 2 pulses per second. Seven of the 10 treated lesions were completely free of basaloid cells when biopsied and two partially regressed. Two of the 7 exhibited seborrheic keratosis in the absence of basaloid cells. One of the 10 treated lesions recurred by week 10 and histologically had the appearance of a squamous cell carcinoma. No scars were visible at the healed sites of any of the successfully ablated lesions. One hundred pulses were sufficient for complete ablation of BCCs with a single, 1‐min nanoelectroablation treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom